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Research question. This paper was done to answer the question on whether patients with IBS require higher analgesic or anxiolytic
doses during colonoscopy. Setting. Gastroenterology practice in Michigan, USA. Methods. We reviewed the charts of patients
following up with a US based gastroenterology practice. We collected data on whether or not they had IBS, and collected data
on analgesic and anxiolytic requirement during colonoscopy. Results. 336 patients were included in the trial. 206 did not have IBS
while 130 had a previous diagnosis of IBS. 234 were female (67.2%). When comparing patients who have IBS to those without
IBS, we identiﬁed no statistically signiﬁcant diﬀerence in midazolam dose (5.5mg versus 5.5mg), fentanyl dose ( 117mg versus
112mg) or meperidine dose (69mg versus 69mg). The lack of diﬀerences in medication doses used remained when we controlled
for sex, prior analgesic use, and prior abdominal surgery. Conclusion. Dose of analgesic or anxiolytic used during colonoscopy
cannot be used to identify patients with IBS.
1.Background
Irritable bowel syndrome (IBS) is a functional GI disorder
characterized by abdominal pain and altered bowel habits.
ExtensivetestingduringworkupforIBSisnotrecommended
[1]. However colonoscopies are commonly done in the di-
agnostic workup of patients with IBS. A 2005 review of col-
onoscopies in the US showed that 23.8% were done for IBS
symptoms [2]. It is also of note that there is no diﬀerence
in prevalence of colonic organic lesions when patients with
IBS are compared to those without IBS [3]. One study noted
that small intestinal biopsy in adults with IBS-like symptoms
revealed microscopic lesions in 81% of patients [4].
Visceral hypersensitivity has been proposed as a mech-
anism of IBS [5]. Some endoscopists also believe that the
patients who remain uncomfortable or require increasing
doses of analgesics and anesthesia have IBS. In our literature
search we found no literature documenting increased anal-
gesic or anxiolytic doses during colonoscopy of patients with
IBS.
2. Justiﬁcation
It is unknown whether patients with IBS require higher anal-
gesic doses during colonoscopy. Documentation of increased
analgesic or anxiolytic doses may be used to diagnose IBS
during colonoscopy, and it may make for safer colonoscopies
for patients with IBS as physicians may use higher doses at
the onset of colonoscopy.
3. Method and Procedures
We carried out a retrospective chart review of patients fol-
lowing with a four physician gastroenterology group that2 ISRN Gastroenterology
Table 1: Age, meperidine, fentanyl, and midazolam dose in patients with IBS compared to patients without IBS.
IBS number mean dose std deviation sig (2 tailed)
Meperidine No 129 69.44 25.243
Yes 94 69.28 23.594 0.962
Fentanyl No 77 112.33 37.252
Yes 36 117.36 30.366 0.449
Midazolam No 206 5.510 1.9044
Yes 130 5.485 2.1404 0.913




No IBS 204 2
Pearson Uncorrected 3.230 (P = 0.072.).
practices in Saginaw, Michigan. Charts were reviewed in
alphabetic order for eligibility and included if they met our
study criteria.
We included into the study charts of patients who were
above the age of 18 years who had undergone colonoscopy.
Werecordedage,sex,analgesiausepriortocolonoscopy,pre-
vious abdominal surgery, analgesia dose at time of colon-
oscopy, and anxiolytic dose at time of colonoscopy.
We also recorded information on indication for colon-
oscopy and postprocedure diagnosis after colonoscopy. BMI,
renal function, and hepatic function within 9 months of the
colonoscopy were recorded if it was available.
We excluded patients who underwent emergency colon-
oscopy, patients who were hemodynamically unstable at the
time of colonoscopy, and patients who were on continuous
IV analgesic drips or on continuous topical analgesic patches
at the time of colonoscopy. Patients who underwent more
than one procedure, for example, esophagogastroscopy and
colonoscopy, were also excluded. Patients undergoing any
procedure other than polypectomy were also excluded.
Patients who primarily received any analgesic other than me-
peridine and fentanyl as the primary analgesic were also
excluded.
3.1.StatisticalAnalysis. ThedoseofanalgesicrequiredinIBS
patients undergoing colonoscopy was compared to dose of
analgesic required in non-IBS patients. The dose of benzo-
diazepine required during colonoscopy in IBS patients was
compared to dose of sedative in non-IBS patients.
All parameters were compared using 2 sided Student
t tests and considered statistically signiﬁcant if a P value of
less than 0.05 was achieved. We then analyzed the data to
checkiftheprespeciﬁedpotentialconfounders(age,previous
abdominal surgery, prior analgesic use, BMI) had inﬂuenced
the results.
3.2. Sample Size Calculation. Using
(i) power 80%,
(ii) alpha 0.05,
(iii) versed dose SD range 2 to 7mg,
(iv) meperidine dose SD range 12.5 to 50mg,
(v) with the intention of using comparison by 2 sample
independent, t test a sample size of 87 was calculated
for each group.
3.3. Ethical Considerations. The study received IRB approval
from Synergy Medical Education Alliance. No personal iden-
tifying data was collected.
4. Results
We reviewed 1260 charts for eligibility and selected 336 for
analysis. We had 234 female and 102 male. The indication
for colonoscopy, gross diagnosis, type of previous abdominal
surgery, renal function, and liver function was also recorded,
and this is given in a supplementary text (see supplementary
Material available online at doi:10.5402/2011/969015).
Of the patient charts selected, seen 206 had no previous
diagnosis of IBS. 130 had a previous diagnosis of IBS.
81.3%ofIBSpatientswerefemalewhereas61.2%ofnon-
IBS patients were female. This was a statistically signiﬁcant
diﬀerence (Pearson chi square 0.000).
PatientswithIBSwerealsomorelikelytohaveundergone
previous abdominal surgery (60.8% versus 46.3%, Pearson
chi square = 0.010).
When the two groups were compared, patients with IBS
were statistically signiﬁcantly younger (46.4 years versus 53.4
years old, P<0.05).
We had valid BMI data (recordings of weight and height
in the 9 months of the colonoscopy) on 87 patients with IBS
and 90 patients without IBS. Mean BMI was 28.4 in the IBS
group versus 31.6 in the non-IBS group (t test P = 0.003).
Patients in both groups had statistically similar amounts
of opiate and non-opiate prior analgesic use (Pearson Chi
Square = 0.216) (see supplement).
On comparing patients with IBS to those without IBS,
we found that the patients used similar doses of meperi-
dine (69.3mg versus 69.4mg), fentanyl (117.4mg versusISRN Gastroenterology 3
Table 3: Female patients’ meperidine, fentanyl and midazolam dose when comparing patients without IBS to patients with IBS.
N MEAN STD DEVIATION Sig (2 tailed)
Meperidine NO IBS 78 69.49 24.81 0.850
IBS 78 68.75 23.64
Fentamyl NO IBS 48 114.05 43.04 0.673
IBS 30 117.50 28.73
Midazolam NO IBS 126 5.68 1.99 0.663
IBS 108 5.57 2.11
N : number, Std deviation: Standard deviation.
Table 4: Meperidine, fentanyl and midazolam dose in patients who have had abdominal surgery compared to those who have not had
abdominal surgery.
N Mean Standard deviation Sig (2 tailed)
Meperidine No surgery
Abd surgery




49 112.76 37.542 0.760
64 114. 84 33.473
Midazolam No surgery
Abd surgery
161 5.612 1.941 0.332
174 5.339 2.051
(Abd: abdominal, N : Number).
112.3mg), or midazolam (5.5mg versus 5.5mg) during col-
onoscopy.
We had a few patients who required additional propofol
when undergoing colonoscopy (Table 2). Patients with IBS
andthose withoutIBSwerestatisticallyaslikely aseachother
to require further analgesia with propofol.
We then carried out sub analysis to see if the lack of dif-
ference in analgesic or anxiolytic dose was inﬂuenced by the
diﬀerences in the two groups.
Weexcludedmalesandlookedatanalgesicandanxiolytic
doses used only in females. We found no statistically signif-
icant diﬀerences in doses of medication used (Table 3).
We had found that IBS patients had more previous ab-
dominal surgeries than non-IBS patients. We however did
not ﬁnd any diﬀerences in analgesic or anxiolytic doses used
in patient who had gone previous surgery versus those who
had not.
Though there were statistically signiﬁcant diﬀerences in
age (see Table 1) and BMI (BMI of 28.4 in patients with
IBS, 31.6 in patients without IBS), we did not feel that these
diﬀerences were clinically signiﬁcant.
5. Discussion
In this paper, patients with IBS were not more likely to
require higher analgesia or anxiolytic medication doses dur-
ingcolonoscopywhencomparedwiththegeneralpopulation
of other patients undergoing colonoscopy.
The lack of diﬀerence could not be explained by group
diﬀerences in sex, age, previous abdominal surgery, previous
analgesic use, or BMI in the comparison groups.
We were able to achieve the predetermined sample size
for analysis of comparison of meperidine and midazolam
doses used in the two groups.
Our study had the same percentage of females identiﬁed
with IBS and following with a physician (81.3%) as a pre-
vious2005survey[6].TheaverageageofpatientswithIBSin
our trial (46.4 years) may have been older than other studies
because our population was people undergoing colonoscopy
and this might have caused a selection bias that skewed the
mean age upwards.
We looked at previous abdominal surgery as a potential
confounder because we thought that patients who have had
abdominal surgery may form increased adhesions, and this
would tether their colons and make them require more
analgesia. This turned out not to be the case (Table 4).
In light of the previous studies on hypersensitivity as a
mechanism of IBS, the most likely explanation for lack of
diﬀerence in medication requirement is the possibility that
initial doses requested by the gastroenterologist were suﬃ-
cient to cause analgesia and relaxation in the same percent of
IBS patients and non-IBS patients.
We also note that previous studies showing hypersensi-
tivity in IBS were done comparing patients with IBS to pa-
tients to the normal population [5] while in our study
population we found that 66.7% of patients had identiﬁable
gross pathology on colonoscopy (see supplement).
We however note some limitations in our study. Anal-
gesia and anxiolytic doses were done at the discretion of
the gastroenterologists, without a formal protocol. We also
notethattheremayhavebeenpatientswithundiagnosedIBS
in the non-IBS group. In a general population survey, this4 ISRN Gastroenterology
percentage of individuals was found to be about 10.8% [6].
We however expect the number in this study to be much
lower as all patients were following up with a gastroenterol-
ogy practice.
In conclusion, our study found no relationship between
analgesic and anxiolytic dose during colonoscopy and the
presence of IBS. We therefore note that medication dosing
during colonoscopy cannot be used by physicians to suspect
IBS and medication for colonoscopy of patients with IBS
should be the same as for the general population undergoing
colonoscopy.
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